Arcturus Therapeutics Holdings INC Form 4 insider transactions

Director Magda Marquet reports the acquisition of stock options and conversion of deferred stock units into common stock at Arcturus Therapeutics Holdings Inc.

Director James F. Barlow exercises deferred stock units and acquires stock options in Arcturus Therapeutics Holdings Inc.

Director Peter Farrell reports acquisition and disposal of Arcturus Therapeutics stock and derivative securities.

Arcturus Therapeutics' Chief Financial Officer, Andy Sassine, sold 50,000 shares of common stock on June 12, 2024, at an average price of $32.03.

Pad Chivukula, Chief Scientific Officer & COO of Arcturus Therapeutics, sold 114 shares of common stock at $45 per share on June 5, 2024, under a pre-arranged 10b5-1 trading plan.

Arcturus Therapeutics' Chief Scientific Officer & COO, Pad Chivukula, sold 26,000 shares of common stock at an average price of $40.009 on June 3, 2024, according to a Form 4 filing.

Pad Chivukula, Chief Scientific Officer & COO of Arcturus Therapeutics, sold 17,435 shares of common stock at an average price of $35.02 on March 25, 2024, under a pre-arranged trading plan.

Pad Chivukula, Chief Scientific Officer & COO of Arcturus Therapeutics, sold 8,565 shares of common stock at an average price of $35.0075 on March 19, 2024, under a pre-arranged Rule 10b5-1 trading plan.